JAZZ News and Press, Jazz Pharmaceuticals plc From 04/20/21

Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes PR Newswire DUBLIN , April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company") announced today that its wholly owned subsidiary, Jazz Securities Des...

Jazz Pharmaceuticals (JAZZ) announces positive results from Phase 3 study of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia.The study design included a titration and optimization period of up to 14 weeks, a Xywav sta...

Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting Xywav demonstrated statistically significant...

Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021 PR Newswire DUBLIN , April 19, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 first quarter financial results on T...

Real Brands Inc (OTCMKTS:RLBD) is an emerging player on the rejuvenating CBD stock landscape, and one that may deserve attention as a squeeze candidate because the stock has been a target for bears, but one that may be entirely misplaced given the company’s recent strong strides toward...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Downward Pressure For Top Marijuana Stocks Marijuana stocks have started this week in April showing some downside in the market. One factor that probably played a part in the downturn in the cannabis sector is a disappointing third-quarter fiscal 2021 report from Aphria Inc. ( NASDAQ:...

Jazz Pharmaceuticals (JAZZ) announces that the U.S. FDA has granted Priority Review designation and confirmed the acceptance for substantive review of the supplemental New Drug Application ((sNDA)) seeking approval for Xywav oral solution in adult patients with idiopathic hypersomnia.The...

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia Final FDA decision anticipated by August 12 Phase 3 study res...

When GW Pharmaceuticals ' (NASDAQ: GWPH) cannabidiol-based drug, Epidiolex, came onto the pharmaceutical scene, cannabis investors rejoiced. Jazz Pharmaceuticals (NASDAQ: JAZZ) recently announced plans to acquire GW Pharma, and to bring its seizure treatment into a larger po...